Precision phage technology for targeted oral malodor control

Overview

Parallel Health's precision phage technology offers a groundbreaking solution to oral malodor by targeting harmful bacteria while preserving beneficial oral microbiome species. Unlike traditional broad-spectrum antimicrobials, this technology uses natural viral particles, phages, to selectively eliminate specific bacterial strains responsible for producing volatile sulfur compounds (VSCs), the primary cause of bad breath. This approach ensures long-lasting freshness without altering taste or causing irritation, making it suitable for products like denture adhesives and other oral applications.

Technical specifications

Key components of the platform include:

• A proprietary database of over 10,000 characterized microbial strains for precise targeting.
• AI-driven genomic analysis for optimal matching of phages to bacteria.
• Scalable phage production capabilities to meet consumer demand.
• Proven expertise in formulating phage-based therapeutics for safe and effective consumer use.

The technology specifically targets anaerobic bacteria like Fusobacterium and Porphyromonas that produce VSCs, offering a microbiome-friendly alternative to harsh chemical agents.

Technology readiness level

Currently at Technology Readiness Level 3, this solution has completed early-stage research and is moving into further validation phases. The ongoing research includes microbiome characterization, phage development, and clinical validation to establish efficacy and safety, with future deliverables including validated phage cocktails and a clinical efficacy package.